Anafranil SR, 75 mg 10 pcs

Anafranil SR is a tricyclic antidepressant, an inhibitor of noradrenaline and serotonin reuptake. The therapeutic effect of Anafranil SR is thought to be due to its ability to inhibit the neuronal reuptake of noradrenaline (NA) and serotonin (5-HT) released into the synaptic gap, the most important being inhibition of serotonin reuptake. Anafranil SR also has a broad spectrum of other pharmacological actions: alpha1-adrenolytic, anticholinergic, antihistamine and antiserotoninergic (5-HT receptor blockade).

Anafranil SR acts on the depressive syndrome in general, including especially on such its typical manifestations as psychomotor retardation, depressed mood and anxiety. Clinical effect is usually observed after 2-3 weeks of treatment. In addition, Anafranil SR has a specific (different from its antidepressant effect) effect in obsessive-compulsive disorders.

The action of Anafranil SR in chronic pain syndromes, whether or not due to somatic diseases, is probably due to the facilitation of nerve impulse transmission mediated by serotonin and noradrenaline.

Indications

Adults:
– treatment of depressive states of various etiologies, occurring with various symptoms: endogenous, reactive, neurotic, organic, masked, involutional forms of depression; depression in patients with schizophrenia and psychopathy; depressive syndromes that occur in old age, caused by chronic pain syndrome or chronic somatic diseases; depressive mood disorders of a reactive, neurotic or psychopathic nature;
— obsessive-compulsive syndromes;
— chronic pain syndrome;
– phobias and panic attacks;
– cataplexy accompanying narcolepsy.
Children and teenagers:
— obsessive-compulsive syndromes;
– nocturnal enuresis (only in patients over 5 years of age and subject to the exclusion of organic causes of the disease).

Pharmacological effect

Anafranil SR is a tricyclic antidepressant, a norepinephrine and serotonin reuptake inhibitor. It is believed that the therapeutic effect of Anafranil SR is due to its ability to inhibit the neuronal reuptake of norepinephrine (NA) and serotonin (5-HT) released into the synaptic cleft, the most important being the inhibition of serotonin reuptake. Anafranil SR, in addition, has a wide range of other pharmacological actions: alpha1-adrenolytic, anticholinergic, antihistamine and antiserotonergic (blockade of 5-HT receptors).

Anafranil SR acts on depressive syndrome in general, incl. especially on such typical manifestations as psychomotor retardation, depressed mood and anxiety. The clinical effect is usually observed after 2-3 weeks of treatment. In addition, Anafranil SR has a specific (different from its antidepressant effect) effect in obsessive-compulsive disorders.

The effect of Anafranil SR in chronic pain syndromes, both caused and not caused by somatic diseases, is probably associated with the facilitation of nerve impulse transmission mediated by serotonin and norepinephrine.

Special instructions

Tricyclic antidepressants are known to lower the seizure threshold, so Anafranil SR should be used with extreme caution in patients with epilepsy.

Patients who experience drowsiness and other central nervous system disorders (including blurred vision) while using Anafranil SR should not drive a car, operate machinery, or engage in other activities that require increased attention and quick reaction.

Active ingredient

Clomipramine

Composition

1 tablet contains clomipramine hydrochloride 75 mg

Contraindications

– hypersensitivity to clomipramine and other components of the drug, cross-hypersensitivity to tricyclic antidepressants from the dibenzazepine group;
– simultaneous use of MAO inhibitors, as well as a period of less than 14 days before and after their use;
– simultaneous use of selective MAO type A inhibitors of reversible action (such as moclobemide);
– recent myocardial infarction;
– congenital long QT interval syndrome.

It is not recommended to use the drug during pregnancy and breastfeeding.
The drug is not recommended for use in children under 5 years of age.

Side Effects

Other: after sudden withdrawal or rapid reduction of the dose of Anafranil SR, the following symptoms often occur: nausea, vomiting, abdominal pain, diarrhea, insomnia, headache, irritability, anxiety.

The observed adverse events are usually mild and transient, disappear with continued treatment or after reducing the dose of Anafranil SR. They do not always correlate with the concentration of the active substance of the drug in the blood plasma or with its dose. Some undesirable effects, such as general weakness, sleep disturbances, agitation, anxiety, constipation, dry mouth, are often difficult to distinguish from manifestations of depression.

In case of serious side effects from the nervous system or mental status, Anafranil SR should be discontinued. Elderly people are especially sensitive to the effects of Anafranil SR on the nervous system, the cardiovascular system, the effect of the drug on mental status, as well as to the anticholinergic effect of Anafranil SR.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Novartis Pharma S.p.A., Italy